Loading
The surgeon on CheckMate 816 who showed neoadjuvant immunotherapy does not make lung cancer operations harder.
Jonathan Spicer led the surgical analyses of CheckMate 816, demonstrating that neoadjuvant nivolumab plus chemotherapy did not delay or complicate surgery and increased the rate of complete resection, which removed a key objection to neoadjuvant immunotherapy. He co-authored the five-year update and leads perioperative surgical research at McGill.
| Title | Journal | Year |
|---|---|---|
| Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer (CheckMate 816) | NEJM | 2022 |
| Surgical outcomes from the phase 3 CheckMate 816 trial: nivolumab plus platinum-doublet chemotherapy vs chemotherapy alone as neoadjuvant treatment for resectable non-small cell lung cancer | JAMA Oncology | 2023 |
Shares CheckMate 816, CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery, Resectable stage I to III non-small-cell lung cancer, Nivolumab and the tags lung, neoadjuvant.
Shares CheckMate 816, CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery, Resectable stage I to III non-small-cell lung cancer, Nivolumab.
Shares Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tags lung, surgery.
Shares CheckMate 816, Non-small-cell lung cancer and the tag surgery.
Shares the tags surgery, neoadjuvant.
Shares the tags surgery, neoadjuvant.
Shares Non-small-cell lung cancer and the tag lung.
Shares Non-small-cell lung cancer and the tag lung.